Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Surgical Wound Infection

Conditions

Surgical Wound Infection, Traumatic Wound Infection

Trial Timeline

Feb 2, 2026 → Oct 28, 2026

About Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC)

Amicidin-β topical solution - 15 mL + Amicidin-β topical solution - 50 mL + Standard of Care (SOC) is a phase 1 stage product being developed by Novo Nordisk for Surgical Wound Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07379684. Target conditions include Surgical Wound Infection, Traumatic Wound Infection.

What happened to similar drugs?

7 of 20 similar drugs in Surgical Wound Infection were approved

Approved (7) Terminated (5) Active (10)
Epoetin alfa + Standard of CareJohnson & JohnsonApproved
ErtapenemMerckApproved
Sugammadex + RocuroniumMerckApproved
Deep neuromuscular blockMerckApproved
RocuroniumMerckApproved
parecoxib/valdecoxibPfizerApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07379684Phase 1Recruiting

Competing Products

20 competing products in Surgical Wound Infection

See all competitors
ProductCompanyStageHype Score
DFA-02 Antibiotic Gel + DFA-02 Placebo GelDr. Reddy's LaboratoriesPhase 2
32
DFA-02 + PlaceboDr. Reddy's LaboratoriesPhase 1/2
29
CelecoxibAstellas PharmaPre-clinical
26
Nivolumab + EverolimusOno PharmaceuticalPhase 3
40
Epoetin alfa + Standard of CareJohnson & JohnsonApproved
35
HR021618 + HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
31
SHR0410 Injection + Placebo for SHR0410 InjectionJiangsu Hengrui MedicinePhase 2
27
ErtapenemMerckApproved
43
Sugammadex + RocuroniumMerckApproved
43
Deep neuromuscular blockMerckApproved
43
RocuroniumMerckApproved
43
ErtapenemMerckPhase 2/3
38
Sugammadex + Neostigmine + GlycopyrrolateMerckPhase 3
40
Ecallantide + PlaceboMerckPhase 2
27
Insulin infusion with a goalNovo NordiskPhase 3
40
parecoxib/valdecoxibPfizerApproved
35
Tranexamic acid + Standard of CarePfizerApproved
43
Ibuprofen 250 mg / Acetaminophen 500 mg + Ibuprofen 250 mg + Acetaminophen 650 mg + PlaceboPfizerPhase 3
40
valdecoxib + valdecoxib/placebo + placeboPfizerPhase 3
40
PF-04531083 + PF-04531083 + IbuprofenPfizerPhase 2
27